This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
STENTING IS A wide-open field. Implanting minute metallic mesh expandable cages to keep coronary arteries patent "is one of the hottest things in cardiology right now," agreed numerous speakers at the 69th Scientific Sessions of the American Heart Association (AHA), held in New Orleans, La. And even as many cardiologists are documenting the ways in which stents provide what one called "a smoother ride" for patients with plaque-prone arteries, others are experimenting with newer models, improved placement methods, and adjunct therapies.
In the 2 years since the Food and Drug Administration (FDA) gave the go-ahead to the Palmaz-Schatz stent (made by Johnson & Johnson, New Brunswick, NJ) —the first and so far only stent approved for use in the United States—the percentage of postangioplasty patients in whom the device is used has risen from approximately 9% to 39%, said Daniel B. Mark, MD, MPH, director of the Outcomes Research
Goldsmith MF. Cardiologists Broaden Use of Stents. JAMA. 1997;277(4):275-276. doi:10.1001/jama.1997.03540280013007